• Zentalis Pharmaceuticals granted non-qualified stock options covering 269,000 common shares to four newly hired employees under its 2022 inducement plan.
• Options were priced at $3.71 per share, matching the Nasdaq closing price on the grant date.
• Award term runs 10 years; vesting spans four years with 25% after year one, then monthly vesting over three years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609011715PRIMZONEFULLFEED9819820) on September 01, 2026, and is solely responsible for the information contained therein.